Venkatesan Jay's Form 4 filing
Serina Therapeutics, Inc. (SER) · filed Jun 22, 2026
- Accession no.
- 0001413350-26-000004
- Filed
- Jun 22, 2026
- Trade date
- May 22-Jun 17, 2026
- Filing delay
- 31 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $1.05K. It was filed 31 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venkatesan JayCIK 0001413350 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | PPurchaseAcquired | +589 | $1.78 | +$1,048.42 | 589 | Direct | |
| Jun 17, 2026 | Common Stock | CConversionAcquired | +224,152 | $2.25 | +$504,342 | 231,705 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | AGrant or awardAcquired | +15,250 | $0.00 | $0 | 15,250 | Direct | |
| Jun 17, 2026 | Common Stock, $0.0001 par value | CConversionDisposed | −222,222 | $2.25 | −$217,181.25 | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.